Firefly Neuroscience (AIFF)
Market Price (7/7/2026): $1.28 | Market Cap: $20.8 MilSector: Information Technology | Industry: Application Software
Firefly Neuroscience (AIFF)
Market Price (7/7/2026): $1.28Market Cap: $20.8 MilSector: Information TechnologyIndustry: Application Software
Investment Highlights Why It Matters Detailed financial logic regarding cash flow yields vs trend-riding momentum.
Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15% Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 1040% Megatrend and thematic driversMegatrends include Neuroscience & Brain Health. Themes include Neurological Diagnostics, AI in Neuroscience, and Neurotherapeutics. | Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -159% | Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.6 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -540% Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 60% Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -482%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -493% Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -47% High stock price volatilityVol 12M is 186% Key risksAIFF key risks include [1] a critical cash burn rate with less than one year of cash runway, Show more. |
| Cash is significant % of market capNet D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -15% |
| Strong revenue growthRev Chg LTMRevenue Change % Last Twelve Months (LTM) is 1040% |
| Megatrend and thematic driversMegatrends include Neuroscience & Brain Health. Themes include Neurological Diagnostics, AI in Neuroscience, and Neurotherapeutics. |
| Weak multi-year price returns2Y Excs Rtn is -117%, 3Y Excs Rtn is -159% |
| Not profitable at operating income levelOp Inc LTMOperating Income, Last Twelve Months is -8.6 Mil, Op Mgn LTMOperating Margin = Operating Income / Revenue Reflects profitability before taxes and before impact of capital structure (interest payments). is -540% |
| Significant share based compensationSBC/Rev LTMShare Based Compensation / Revenue (Sales), Last Twelve Months (LTM) is 60% |
| Not cash flow generativeCFO/Rev LTMCash Flow from Operations / Revenue (Sales), Last Twelve Months (LTM) is -482%, FCF/Rev LTMFree Cash Flow / Revenue (Sales), Last Twelve Months (LTM) is -493% |
| Yield minus risk free rate is negativeERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -47% |
| High stock price volatilityVol 12M is 186% |
| Key risksAIFF key risks include [1] a critical cash burn rate with less than one year of cash runway, Show more. |
Qualitative Assessment
AI Analysis | Feedback
Updated on 7/1/2026
Firefly Neuroscience (AIFF) stock has lost about 40% since 3/31/2026 because of the following key factors:
1. Termination of a $1 million financing agreement in fiscal Q2 2026 raised concerns about Firefly Neuroscience's financial flexibility.
On June 25, 2026, Firefly Neuroscience and an accredited investor mutually agreed to terminate a securities purchase agreement that would have provided up to $1 million in gross proceeds from the sale of 666,667 units at $1.50 per unit. This termination, affecting potential near-term funding, occurred for a company with a market capitalization around $21 million, signaling a possible need for alternative financing.
2. Persistent unprofitability and significant cash burn continued to weigh on the company's valuation.
Firefly Neuroscience remains unprofitable, reporting a net loss of $8.96 million for the twelve months ending fiscal Q1 2026. While the net loss of $1.91 million in fiscal Q1 2026 narrowed by 89% year-over-year, analysts highlighted "very weak profitability and significant ongoing cash burn" as key factors suppressing the stock price.
Show more
Firefly Neuroscience (AIFF) stock has lost about 40% since 3/31/2026 because of the following key factors:
1. Termination of a $1 million financing agreement in fiscal Q2 2026 raised concerns about Firefly Neuroscience's financial flexibility.
On June 25, 2026, Firefly Neuroscience and an accredited investor mutually agreed to terminate a securities purchase agreement that would have provided up to $1 million in gross proceeds from the sale of 666,667 units at $1.50 per unit. This termination, affecting potential near-term funding, occurred for a company with a market capitalization around $21 million, signaling a possible need for alternative financing.
2. Persistent unprofitability and significant cash burn continued to weigh on the company's valuation.
Firefly Neuroscience remains unprofitable, reporting a net loss of $8.96 million for the twelve months ending fiscal Q1 2026. While the net loss of $1.91 million in fiscal Q1 2026 narrowed by 89% year-over-year, analysts highlighted "very weak profitability and significant ongoing cash burn" as key factors suppressing the stock price.
Show more
Updated on 7/1/2026
Firefly Neuroscience (AIFF) stock has lost about 40% since 3/31/2026 because of the following key factors:
1. Termination of a $1 million financing agreement in fiscal Q2 2026 raised concerns about Firefly Neuroscience's financial flexibility.
On June 25, 2026, Firefly Neuroscience and an accredited investor mutually agreed to terminate a securities purchase agreement that would have provided up to $1 million in gross proceeds from the sale of 666,667 units at $1.50 per unit. This termination, affecting potential near-term funding, occurred for a company with a market capitalization around $21 million, signaling a possible need for alternative financing.
2. Persistent unprofitability and significant cash burn continued to weigh on the company's valuation.
Firefly Neuroscience remains unprofitable, reporting a net loss of $8.96 million for the twelve months ending fiscal Q1 2026. While the net loss of $1.91 million in fiscal Q1 2026 narrowed by 89% year-over-year, analysts highlighted "very weak profitability and significant ongoing cash burn" as key factors suppressing the stock price.
3. Negative analyst sentiment contributed to a lack of investor confidence.
One Wall Street analyst issued a "Sell" rating for AIFF, indicating a cautious outlook on the company's prospects. The consensus among analysts rates Firefly Neuroscience less favorably compared to other companies in the "business services" sector.
4. High stock volatility and mixed sector sentiment amplified downward pressure.
The stock experienced considerable volatility, with a 6.82% drop on June 29, 2026 alone, and a 19.08% decline over a 10-day period leading up to that date. The broader neuroscience and healthcare technology sector has been characterized by mixed sentiment, with investors prioritizing companies that demonstrate clear pipeline milestones or consistent revenue growth potential, further impacting AIFF given its financial position and speculative nature.
Show less
Firefly Neuroscience (AIFF) stock has lost about 40% since 3/31/2026 because of the following key factors:
1. Termination of a $1 million financing agreement in fiscal Q2 2026 raised concerns about Firefly Neuroscience's financial flexibility.
On June 25, 2026, Firefly Neuroscience and an accredited investor mutually agreed to terminate a securities purchase agreement that would have provided up to $1 million in gross proceeds from the sale of 666,667 units at $1.50 per unit. This termination, affecting potential near-term funding, occurred for a company with a market capitalization around $21 million, signaling a possible need for alternative financing.
2. Persistent unprofitability and significant cash burn continued to weigh on the company's valuation.
Firefly Neuroscience remains unprofitable, reporting a net loss of $8.96 million for the twelve months ending fiscal Q1 2026. While the net loss of $1.91 million in fiscal Q1 2026 narrowed by 89% year-over-year, analysts highlighted "very weak profitability and significant ongoing cash burn" as key factors suppressing the stock price.
3. Negative analyst sentiment contributed to a lack of investor confidence.
One Wall Street analyst issued a "Sell" rating for AIFF, indicating a cautious outlook on the company's prospects. The consensus among analysts rates Firefly Neuroscience less favorably compared to other companies in the "business services" sector.
4. High stock volatility and mixed sector sentiment amplified downward pressure.
The stock experienced considerable volatility, with a 6.82% drop on June 29, 2026 alone, and a 19.08% decline over a 10-day period leading up to that date. The broader neuroscience and healthcare technology sector has been characterized by mixed sentiment, with investors prioritizing companies that demonstrate clear pipeline milestones or consistent revenue growth potential, further impacting AIFF given its financial position and speculative nature.
Show less
Holding a concentrated position? Know your true downside before the momentum shifts.
Protect Your Wealth →
Stock Movement Drivers
Fundamental Drivers
The -41.3% change in AIFF stock from 3/31/2026 to 7/6/2026 was primarily driven by a -49.5% change in the company's P/S Multiple.| (LTM values as of) | 3312026 | 7062026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.18 | 1.28 | -41.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 2 | 38.7% |
| P/S Multiple | 26.0 | 13.1 | -49.5% |
| Shares Outstanding (Mil) | 14 | 16 | -16.1% |
| Cumulative Contribution | -41.3% |
Market Drivers
3/31/2026 to 7/6/2026| Return | Correlation | |
|---|---|---|
| AIFF | -41.3% | |
| Market (SPY) | 15.5% | 4.7% |
| Sector (XLK) | 38.1% | 4.3% |
Fundamental Drivers
The 46.3% change in AIFF stock from 12/31/2025 to 7/6/2026 was primarily driven by a 102.3% change in the company's Total Revenues ($ Mil).| (LTM values as of) | 12312025 | 7062026 | Change |
|---|---|---|---|
| Stock Price ($) | 0.88 | 1.28 | 46.3% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 1 | 2 | 102.3% |
| P/S Multiple | 15.1 | 13.1 | -13.1% |
| Shares Outstanding (Mil) | 13 | 16 | -16.8% |
| Cumulative Contribution | 46.3% |
Market Drivers
12/31/2025 to 7/6/2026| Return | Correlation | |
|---|---|---|
| AIFF | 46.3% | |
| Market (SPY) | 10.5% | 1.0% |
| Sector (XLK) | 27.7% | 1.2% |
Fundamental Drivers
The -54.8% change in AIFF stock from 6/30/2025 to 7/6/2026 was primarily driven by a -68.0% change in the company's Shares Outstanding (Mil).| (LTM values as of) | 6302025 | 7062026 | Change |
|---|---|---|---|
| Stock Price ($) | 2.83 | 1.28 | -54.8% |
| Change Contribution By: | |||
| Total Revenues ($ Mil) | 2 | 2 | -23.8% |
| P/S Multiple | 7.1 | 13.1 | 85.4% |
| Shares Outstanding (Mil) | 5 | 16 | -68.0% |
| Cumulative Contribution | -54.8% |
Market Drivers
6/30/2025 to 7/6/2026| Return | Correlation | |
|---|---|---|
| AIFF | -54.8% | |
| Market (SPY) | 22.6% | 7.1% |
| Sector (XLK) | 45.6% | 6.4% |
Fundamental Drivers
nullnull
Market Drivers
6/30/2023 to 7/6/2026| Return | Correlation | |
|---|---|---|
| AIFF | -86.0% | |
| Market (SPY) | 75.5% | 7.5% |
| Sector (XLK) | 115.1% | 5.5% |
Price Returns Compared
| 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | Total [1] | |
|---|---|---|---|---|---|---|---|
| Returns | |||||||
| AIFF Return | 241% | -90% | -65% | -48% | -67% | 47% | -97% |
| Peers Return | -22% | -26% | 140% | -18% | 7% | -11% | 7% |
| S&P 500 Return | 27% | -19% | 24% | 23% | 16% | 9% | 99% |
Monthly Win Rates [3] | |||||||
| AIFF Win Rate | 58% | 17% | 42% | 42% | 25% | 43% | |
| Peers Win Rate | 31% | 40% | 46% | 48% | 42% | 46% | |
| S&P 500 Win Rate | 75% | 42% | 67% | 75% | 67% | 43% | |
Max Drawdowns [4] | |||||||
| AIFF Max Drawdown | -34% | -93% | -90% | -78% | -94% | -61% | |
| Peers Max Drawdown | -58% | -69% | -53% | -62% | -57% | -43% | |
| S&P 500 Max Drawdown | -5% | -25% | -10% | -8% | -19% | -9% | |
[1] Cumulative total returns since the beginning of 2021
[2] Peers: CBLL, NMTC, STIM, NPCE, LIVN.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2026 data is for the year up to 7/6/2026 (YTD)
How Low Can It Go
| Event | AIFF | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -59.0% | -9.5% |
| % Gain to Breakeven | 143.7% | 10.5% |
| Time to Breakeven | 12 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -23.1% | -33.7% |
| % Gain to Breakeven | 30.1% | 50.9% |
| Time to Breakeven | 8 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -42.0% | -19.2% |
| % Gain to Breakeven | 72.4% | 23.8% |
| Time to Breakeven | 64 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -21.3% | -3.7% |
| % Gain to Breakeven | 27.1% | 3.9% |
| Time to Breakeven | 39 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -32.4% | -12.2% |
| % Gain to Breakeven | 47.8% | 13.9% |
| Time to Breakeven | 24 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -32.4% | -6.8% |
| % Gain to Breakeven | 47.8% | 7.3% |
| Time to Breakeven | 24 days | 15 days |
In The Past
Firefly Neuroscience's stock fell -0.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
| Event | AIFF | S&P 500 |
|---|---|---|
| Summer-Fall 2023 Five Percent Yield Shock | ||
| % Loss | -59.0% | -9.5% |
| % Gain to Breakeven | 143.7% | 10.5% |
| Time to Breakeven | 12 days | 24 days |
| 2020 COVID-19 Crash | ||
| % Loss | -23.1% | -33.7% |
| % Gain to Breakeven | 30.1% | 50.9% |
| Time to Breakeven | 8 days | 140 days |
| Q4 2018 Fed Policy Error / Growth Scare | ||
| % Loss | -42.0% | -19.2% |
| % Gain to Breakeven | 72.4% | 23.8% |
| Time to Breakeven | 64 days | 105 days |
| 2016-2017 Trump Reflation Bond Selloff | ||
| % Loss | -21.3% | -3.7% |
| % Gain to Breakeven | 27.1% | 3.9% |
| Time to Breakeven | 39 days | 6 days |
| 2015-2016 China Devaluation / Global Growth Scare | ||
| % Loss | -32.4% | -12.2% |
| % Gain to Breakeven | 47.8% | 13.9% |
| Time to Breakeven | 24 days | 62 days |
| 2014-2016 Oil Price Collapse | ||
| % Loss | -32.4% | -6.8% |
| % Gain to Breakeven | 47.8% | 7.3% |
| Time to Breakeven | 24 days | 15 days |
| 2013 Taper Tantrum | ||
| % Loss | -24.2% | -0.2% |
| % Gain to Breakeven | 32.0% | 0.2% |
| Time to Breakeven | 91 days | 1 days |
| 2011 US Debt Ceiling Crisis & European Contagion | ||
| % Loss | -25.0% | -17.9% |
| % Gain to Breakeven | 33.3% | 21.8% |
| Time to Breakeven | 26 days | 123 days |
| 2008-2009 Global Financial Crisis | ||
| % Loss | -88.2% | -53.4% |
| % Gain to Breakeven | 750.0% | 114.4% |
| Time to Breakeven | 247 days | 1085 days |
In The Past
Firefly Neuroscience's stock fell -0.5% during the 2024 Yen Carry Trade Unwind. Such a loss loss requires a 0.5% gain to breakeven.
Preserve Wealth
Limiting losses and compounding gains is essential to preserving wealth.
Asset Allocation
Actively managed asset allocation strategies protect wealth. Learn more.
About Firefly Neuroscience (AIFF)
```html
Firefly Neuroscience, Inc. (AIFF) is a medical technology and artificial intelligence company based in Toronto, Canada. The company focuses on developing neuroscientific solutions designed to enhance outcomes for patients grappling with various mental illnesses and neurological disorders.
The core of Firefly Neuroscience's offering is its Brain Network Analytics (BNA) software. This specialized software platform aids in both the diagnosis and treatment of a range of mental and cognitive conditions. These include significant disorders such as depression, different forms of dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder (ADHD).
Firefly Neuroscience serves two primary customer segments with its innovative solutions: pharmaceutical companies, who can utilize the BNA software for research, development, or clinical trials, and medical practitioners, who integrate the software into their clinical practice for patient diagnosis and treatment planning.
```AI Analysis | Feedback
Here are 1-3 brief analogies for Firefly Neuroscience (AIFF):
- Like Tempus for brain disorders.
- Like PathAI for brain diagnostics.
- Like Palantir for brain health data analysis.
AI Analysis | Feedback
- Brain Network Analytics: A software solution focused on the diagnosis and treatment of various mental illnesses and neurological disorders, including depression, dementia, and anxiety.
AI Analysis | Feedback
Major Customers of Firefly Neuroscience (AIFF)
Firefly Neuroscience sells its solutions primarily to other companies and professional entities. Based on the provided description, its major customers fall into the following categories:
- Pharmaceutical Companies: These companies utilize Firefly Neuroscience's Brain Network Analytics (BNA) software, likely for research, development, and clinical applications in the field of mental illnesses and neurological disorders. The description does not list specific names of pharmaceutical companies.
- Medical Practitioners: This category includes individual doctors, clinics, and other healthcare organizations. These practitioners use the BNA software for diagnostic and treatment purposes to improve outcomes for patients suffering from conditions such as depression, dementia, anxiety disorders, concussions, and attention-deficit/hyperactivity disorder.
AI Analysis | Feedback
null
AI Analysis | Feedback
Greg Lipschitz, Chief Executive Officer
Greg Lipschitz was appointed CEO of Firefly Neuroscience in March 2025, having previously served as Interim CEO from January 2025 and Executive Chairman from December 2024 to March 2025. He has been on the company's Board since at least December 2022. With over 15 years of experience in private equity, investment banking, capital markets, and advisory roles, he has advised on transactions exceeding $1 billion. His past roles include Managing Director of Old Stone Advisors and former Vice President of Lazer Capital. He is also a Chartered Financial Analyst.
Paul Krzywicki, Chief Financial OfficerPaul Krzywicki has served as the Chief Financial Officer of Firefly Neuroscience since March 2024, after joining the company as Controller in November 2023. He is a licensed CPA with over 15 years of experience in finance and operations. Krzywicki's background includes leadership positions at Nucor Canada, EllisDon, and Canadian Curtis Refrigeration, where he focused on modernization and operating efficiency. He also previously served as Division Controller for a startup company.
Dave DeCaprio, President & COODave DeCaprio was appointed President and Chief Operating Officer of Firefly Neuroscience in April 2025. He is a co-founder of ClosedLoop.ai, which was recognized as the #1 AI Software Solution for Health Care in both 2022 and 2023. DeCaprio brings over 20 years of experience in successfully transitioning advanced technology from academic research laboratories into thriving businesses.
Gil Issachar, Chief Technology OfficerGil Issachar serves as the Chief Technology Officer at Firefly Neuroscience. He is an accomplished technology leader with over 11 years of experience in software development, algorithm design, data science, and research. Issachar holds a Master's degree in Biomedical Engineering, with his thesis focusing on signal processing and neuroscience.
AI Analysis | Feedback
Key Business Risks for Firefly Neuroscience (AIFF)
- Precarious Financial Health and Profitability: Firefly Neuroscience faces significant financial challenges, evidenced by substantial operating losses, negative net income, and a rapid cash burn rate. The company's low revenue, particularly in comparison to its high expenses for research and development and commercialization efforts, raises concerns about its long-term financial viability. An Altman Z-Score of -15.42 indicates a potential risk of bankruptcy, and a Beneish M-Score of 12.58 suggests possible financial manipulation. The stock has also experienced high volatility and has underperformed the broader market and the US Healthcare Services industry.
- Regulatory and Clinical Validation Challenges for AI in Mental Health: Operating in the medical technology and artificial intelligence sector for mental health and neurological disorders, Firefly Neuroscience is subject to evolving and stringent regulatory requirements. The rapid advancement of AI in mental health has outpaced scientific validation and regulatory oversight, leading to concerns about the safety, quality, and accountability of AI tools that are not regulated like licensed medical services. There is a risk of AI providing inaccurate, dismissive, or even harmful advice, particularly in crisis situations. The company must navigate complex compliance to avoid fines, recalls, and loss of market access, and demonstrate rigorous clinical validation, ethical transparency, and human oversight for its Brain Network Analytics (BNA™) platform.
- Intense Competition and Market Adoption Hurdles: Firefly Neuroscience operates in a crowded and highly competitive neurodiagnostics market. It faces numerous direct competitors offering similar EEG analysis platforms and broader competition from larger technology and medical device companies utilizing AI in neurology. Successfully commercializing new AI-driven solutions and achieving widespread adoption by medical practitioners, who can be conservative in embracing new technologies for sensitive areas like mental health, poses a significant challenge. The market often adopts a "wait and see" attitude towards companies with exciting technology but unproven financials, further complicating market penetration.
AI Analysis | Feedback
null
AI Analysis | Feedback
The addressable markets for Firefly Neuroscience's main products and services, which include its Brain Network Analytics software for diagnosing and treating mental illnesses and neurological disorders, are substantial on a global scale.
The estimated global market sizes for the relevant areas are as follows:
- Global Mental Health Market (Diagnostics and Treatment): The global mental illnesses market size was valued at approximately USD 460.6 billion in 2025 and is projected to reach USD 824.53 billion by 2033. Another report indicates the global mental health market size is expected to be around USD 490.91 billion in 2025, growing to USD 682.51 billion by 2035. The broader global neuroscience market, encompassing diagnostics and treatment for brain disorders, was valued at USD 612 billion in 2022 and is forecast to grow to USD 721 billion by 2026.
- Global Neurological Diagnostics Market: This market was estimated at USD 19.01 billion in 2025 and is projected to reach USD 36.57 billion by 2033.
- Global Depression Treatment Market: The global anxiety disorders and depression treatment market size was estimated at USD 15.42 billion in 2024 and is projected to reach USD 19.28 billion by 2030.
- Global Dementia Treatment Market: This market was estimated at USD 18.03 billion in 2024 and is projected to reach USD 28.11 billion by 2030. Another projection places the global dementia treatment market at USD 19.98 billion in 2025, expected to reach USD 40.64 billion by 2034.
- Global Anxiety Disorders Treatment Market: This market is projected to increase from USD 12.33 billion in 2025 to USD 17.56 billion by 2035.
- Global Concussion Market (Diagnostics and Treatment): The global concussion market size was estimated at USD 6.58 billion in 2024 and is projected to reach USD 9.31 billion by 2030.
- Global Attention-Deficit/Hyperactivity Disorder (ADHD) Treatment Market: The global Attention-Deficit Hyperactivity Disorder (ADHD) market was valued at USD 18.75 billion in 2024 and is expected to reach USD 32.90 billion by 2032. The global ADHD therapeutics market was valued at USD 35.17 billion in 2024 and is projected to reach USD 76.96 billion by 2033.
AI Analysis | Feedback
Firefly Neuroscience, Inc. (AIFF) is expected to drive future revenue growth over the next 2-3 years through several key initiatives:
- Commercial Footprint Expansion and Partnership Growth: The company has demonstrated significant expansion of its commercial footprint, growing over 20-fold, and has increased its partnerships to 99 commercial sites by the end of 2025. This expanding network of commercial users and partner sites is anticipated to enhance market penetration and broaden access to its neuroscientific solutions.
- Increased EEG/ERP Brain Scan Volumes: Directly related to its expansion efforts, Firefly Neuroscience reported a substantial 33-fold increase in EEG/ERP brain scan volumes, reaching over 10,800 scans by the end of 2025. This surge in clinical assessments indicates a rising demand and adoption of its Brain Network Analytics platform, which is expected to translate into higher revenue.
- Strategic Acquisition of Evoke Neuroscience: The acquisition of Evoke Neuroscience has been identified as a strategic initiative that has fueled Firefly's commercial reach and increased scan volumes. The integration of Evoke's assets and customer base is expected to continue contributing to the company's revenue growth.
- Advancements in AI-Driven Biomarker Discovery and Foundation Model Development: Firefly Neuroscience is leveraging NVIDIA L40S GPU acceleration to advance AI-driven biomarker discovery and is progressing towards developing the world's first EEG/ERP-based foundation model of the human brain. These technological innovations are poised to enhance existing offerings and potentially create new revenue streams through advanced diagnostic and treatment tools.
- Expansion of Clinical Applications, particularly ADHD Subtype Identification: The company's AI-powered technology to identify ADHD subtypes represents a specific clinical application that recently garnered significant market attention. Expanding the proven utility of its Brain Network Analytics platform for various mental illnesses and neurological disorders, such as identifying different ADHD subtypes, will open new market opportunities and revenue streams.
AI Analysis | Feedback
Capital Allocation Decisions for Firefly Neuroscience (AIFF)
Share Issuance
- In March 2026, Firefly Neuroscience completed an initial private placement, issuing 1.5 million units for $2.25 million. Investors also have the right to purchase up to an additional $18 million in units within 30 days after the initial closing.
- In February 2026, the company entered into an At-the-Market (ATM) Offering Agreement, authorizing the sale of up to $7.43 million worth of common stock.
- In February 2025, stockholders approved two significant stock issuances as part of a financing strategy from December 2024, involving shares for Helena Special Opportunities LLC and Arena Business Solutions Global SPC II, Ltd.
Inbound Investments
- An initial closing in March 2026 generated $2.25 million from accredited investors through a private placement, with an option for these investors to provide up to an additional $18 million.
- Stockholder approvals in February 2025 facilitated share issuances to Helena Special Opportunities LLC and Arena Business Solutions Global SPC II, Ltd., representing inbound investments into the company.
Outbound Investments
- The company's expansion involved the acquisition of Evoke Neuroscience, Inc.
Capital Expenditures
- In the last 12 months as of March 2026, Firefly Neuroscience reported capital expenditures of -$185,000.
- The company is focused on expanding its compute capabilities, including the deployment of NVIDIA L40S GPU acceleration for EEG/ERP processing.
Latest Trefis Analyses
| Title | Date | |
|---|---|---|
| DASHBOARDS | ||
| Firefly Neuroscience Earnings Notes | 12/16/2025 | |
| Can Firefly Neuroscience Stock Recover If Markets Fall? | 10/17/2025 |
| Title | |
|---|---|
| ARTICLES |
Research & Analysis
Invest in Strategies
Wealth Management
Peer Comparisons
| Peers to compare with: |
Financials
| Median | |
|---|---|
| Name | |
| Mkt Price | 10.21 |
| Mkt Cap | 0.3 |
| Rev LTM | 97 |
| Op Inc LTM | -13 |
| FCF LTM | -9 |
| FCF 3Y Avg | -12 |
| CFO LTM | -9 |
| CFO 3Y Avg | -11 |
Growth & Margins
| Median | |
|---|---|
| Name | |
| Rev Chg LTM | 50.8% |
| Rev Chg 3Y Avg | 30.6% |
| Rev Chg Q | 21.8% |
| QoQ Delta Rev Chg LTM | 5.0% |
| Op Inc Chg LTM | 14.4% |
| Op Inc Chg 3Y Avg | 12.9% |
| Op Mgn LTM | -43.9% |
| Op Mgn 3Y Avg | -33.4% |
| QoQ Delta Op Mgn LTM | 0.6% |
| CFO/Rev LTM | -30.3% |
| CFO/Rev 3Y Avg | -24.0% |
| FCF/Rev LTM | -31.3% |
| FCF/Rev 3Y Avg | -25.1% |
Price Behavior
Price Behavior
| Market Price | $1.28 | |
| Market Cap ($ Bil) | 0.0 | |
| First Trading Date | 01/03/2007 | |
| Distance from 52W High | -59.5% | |
| 50 Days | 200 Days | |
| DMA Price | $2.18 | $2.48 |
| DMA Trend | down | down |
| Distance from DMA | -41.3% | -48.5% |
| 3M | 1YR | |
| Volatility | 90.2% | 187.2% |
| Downside Capture | 270.75 | 260.75 |
| Upside Capture | -31.25 | 98.37 |
| Correlation (SPY) | 3.0% | 7.1% |
AIFF Betas & Captures as of 6/30/2026
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
| 1M | 2M | 3M | 6M | 1Y | 3Y | |
|---|---|---|---|---|---|---|
| Beta | 0.47 | 0.45 | 0.32 | 0.26 | 1.06 | 1.01 |
| Up Beta | -2.51 | -2.68 | -1.04 | -0.23 | 0.62 | 0.51 |
| Down Beta | 0.58 | 1.24 | 0.24 | -2.18 | -0.11 | 0.76 |
| Up Capture | -94% | -107% | -36% | 185% | 99% | 67% |
| Bmk +ve Days | 11 | 24 | 40 | 67 | 140 | 429 |
| Stock +ve Days | 7 | 13 | 24 | 50 | 105 | 326 |
| Down Capture | 279% | 287% | 277% | 120% | 172% | 111% |
| Bmk -ve Days | 10 | 17 | 23 | 58 | 112 | 321 |
| Stock -ve Days | 13 | 24 | 34 | 69 | 135 | 407 |
[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively
Based On 1-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIFF | |
|---|---|---|---|---|
| AIFF | -57.8% | 187.2% | 0.18 | - |
| Sector ETF (XLK) | 45.6% | 24.1% | 1.50 | 6.4% |
| Equity (SPY) | 22.2% | 12.5% | 1.32 | 6.9% |
| Gold (GLD) | 23.7% | 27.8% | 0.75 | 2.0% |
| Commodities (DBC) | 21.2% | 18.6% | 0.90 | 9.1% |
| Real Estate (VNQ) | 12.4% | 13.8% | 0.61 | 7.0% |
| Bitcoin (BTCUSD) | -43.6% | 42.7% | -1.23 | 19.3% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 5-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIFF | |
|---|---|---|---|---|
| AIFF | -57.1% | 175.2% | 0.18 | - |
| Sector ETF (XLK) | 21.3% | 25.4% | 0.74 | 7.7% |
| Equity (SPY) | 13.5% | 17.1% | 0.61 | 10.2% |
| Gold (GLD) | 18.1% | 18.3% | 0.80 | 2.8% |
| Commodities (DBC) | 7.3% | 19.5% | 0.27 | 4.6% |
| Real Estate (VNQ) | 2.7% | 18.9% | 0.05 | 10.9% |
| Bitcoin (BTCUSD) | 14.2% | 53.6% | 0.45 | 5.1% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Based On 10-Year Data
| Annualized Return | Annualized Volatility | Sharpe Ratio | Correlation with AIFF | |
|---|---|---|---|---|
| AIFF | -22.8% | 172.6% | 0.45 | - |
| Sector ETF (XLK) | 24.9% | 24.8% | 0.91 | 7.0% |
| Equity (SPY) | 15.4% | 18.0% | 0.73 | 8.8% |
| Gold (GLD) | 12.3% | 16.1% | 0.62 | 2.5% |
| Commodities (DBC) | 5.8% | 18.0% | 0.25 | 2.8% |
| Real Estate (VNQ) | 5.4% | 20.7% | 0.22 | 7.6% |
| Bitcoin (BTCUSD) | 58.3% | 66.2% | 0.98 | 3.5% |
Smart multi-asset allocation framework can stack odds in your favor. Learn How
Returns Analyses
Earnings Returns History
Updated 6/2/2026| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/4/2024 | 2.8% | -5.3% | -15.5% |
| 11/21/2022 | -21.1% | -28.2% | -44.7% |
| 8/15/2022 | 9.1% | 11.6% | -4.1% |
| 5/23/2022 | -6.6% | 4.9% | -28.8% |
| 11/3/2021 | -9.5% | -13.8% | -9.7% |
| 8/18/2021 | -3.8% | 3.8% | 15.0% |
| 5/18/2021 | -2.6% | 7.7% | 31.9% |
| 2/17/2021 | 17.6% | 4.0% | 45.7% |
| ... | |||
| SUMMARY STATS | |||
| # Positive | 5 | 7 | 5 |
| # Negative | 5 | 3 | 5 |
| Median Positive | 9.1% | 7.7% | 45.7% |
| Median Negative | -6.6% | -13.8% | -15.5% |
| Max Positive | 51.5% | 27.3% | 106.1% |
| Max Negative | -21.1% | -28.2% | -44.7% |
| Forward Returns | |||
|---|---|---|---|
| Earnings Date | 1D Returns | 5D Returns | 21D Returns |
| 12/4/2024 | 2.8% | -5.3% | -15.5% |
| 11/21/2022 | -21.1% | -28.2% | -44.7% |
| 8/15/2022 | 9.1% | 11.6% | -4.1% |
| 5/23/2022 | -6.6% | 4.9% | -28.8% |
| 11/3/2021 | -9.5% | -13.8% | -9.7% |
| 8/18/2021 | -3.8% | 3.8% | 15.0% |
| 5/18/2021 | -2.6% | 7.7% | 31.9% |
| 2/17/2021 | 17.6% | 4.0% | 45.7% |
| 11/16/2020 | 6.3% | 26.6% | 50.6% |
| 8/18/2020 | 51.5% | 27.3% | 106.1% |
| SUMMARY STATS | |||
| # Positive | 5 | 7 | 5 |
| # Negative | 5 | 3 | 5 |
| Median Positive | 9.1% | 7.7% | 45.7% |
| Median Negative | -6.6% | -13.8% | -15.5% |
| Max Positive | 51.5% | 27.3% | 106.1% |
| Max Negative | -21.1% | -28.2% | -44.7% |
Insider Activity
Updated 4/26/2026| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Windsor, Private Capital LP | See footnote | Sell | 10222025 | 2.07 | 78,031 | 161,735 | 2,563,459 | Form | |
| 2 | Windsor, Private Capital LP | See footnote | Sell | 10222025 | 2.40 | 19,222 | 46,140 | 3,156,056 | Form | |
| 3 | Windsor, Private Capital LP | See footnote | Sell | 10222025 | 2.46 | 33,500 | 82,310 | 3,277,702 | Form | |
| 4 | Windsor, Private Capital LP | See footnote | Sell | 10172025 | 2.55 | 45,036 | 114,671 | 3,481,995 | Form | |
| 5 | Windsor, Private Capital LP | See footnote | Sell | 10172025 | 2.65 | 40,139 | 106,457 | 3,746,397 | Form |
| # | Owner | Title | Holding | Action | Filing Date | Price | Shares | Transacted Value | Value of Held Shares | Form |
|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Windsor, Private Capital LP | See footnote | Sell | 10222025 | 2.07 | 78,031 | 161,735 | 2,563,459 | Form | |
| 2 | Windsor, Private Capital LP | See footnote | Sell | 10222025 | 2.40 | 19,222 | 46,140 | 3,156,056 | Form | |
| 3 | Windsor, Private Capital LP | See footnote | Sell | 10222025 | 2.46 | 33,500 | 82,310 | 3,277,702 | Form | |
| 4 | Windsor, Private Capital LP | See footnote | Sell | 10172025 | 2.55 | 45,036 | 114,671 | 3,481,995 | Form | |
| 5 | Windsor, Private Capital LP | See footnote | Sell | 10172025 | 2.65 | 40,139 | 106,457 | 3,746,397 | Form | |
| 6 | Windsor, Private Capital LP | See footnote | Sell | 10172025 | 2.74 | 17,500 | 48,027 | 3,986,793 | Form | |
| 7 | Windsor, Private Capital LP | See footnote | Sell | 10142025 | 2.74 | 29,500 | 80,800 | 4,026,881 | Form | |
| 8 | Windsor, Private Capital LP | See footnote | Sell | 10142025 | 2.65 | 32,136 | 85,241 | 3,977,957 | Form | |
| 9 | Windsor, Private Capital LP | See footnote | Sell | 10142025 | 2.70 | 74,810 | 201,942 | 4,135,041 | Form | |
| 10 | Windsor, Private Capital LP | See footnote | Sell | 10142025 | 2.94 | 30,126 | 88,694 | 4,730,129 | Form |
Firefly Neuroscience — Investor Video Playlist
Products & Services
Firefly Demo Evoke Technology
Products & Services
Using Simcheck for Mental Health Assessments
Products & Services
Recognizing Traumatic Brain Injury (TBI) with HRV, ERP, and EEG Biomarkers
Products & Services
Memory Loss & Early Detection with Dr. Hagedorn
Products & Services
Using EVOX for Chronic Pain – Lunch & Learn Webinar
Products & Services
Recognizing Depression with Evox – Lunch & Learn Webinar
Products & Services
Aiding Differential Diagnosis
Industry Resources
| Information Technology Resources |
| TechCrunch |
| Wired |
| CIO |
| MIT Technology Review |
| Gartner Insights |
| Ars Technica |
| Application Software Resources |
| Capterra |
| Software Advice |
| InfoWorld |
External Quote Links
| Y Finance | Barrons |
| TradingView | Morningstar |
| SeekingAlpha | ValueLine |
| Motley Fool | Robinhood |
| CNBC | Etrade |
| MarketWatch | Unusual Whales |
| YCharts | Perplexity Finance |
| FinViz |
Prefer one of these to Trefis? Tell us why.
Core Cache Last Updated: 7/6/2026